Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DexCom, Inc.

http://www.dexcom.com

Latest From DexCom, Inc.

FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion

Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.

FDA Approvals

News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic

Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind. 

Regulation Policy

Dexcom Doubles Down On Jonas Branding To Hail G7 Launch

Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.

Consumer Launches

Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch

The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.

Diabetic Care Approvals
See All

Company Information

  • Industry
  • Medical Devices
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Other Names / Subsidiaries
    • SweetSpot Diabetes Care
    • TypeZero Technologies, LLC
UsernamePublicRestriction

Register